Advances in Cancer Immunotherapy™: A Focus on Toxicity Management - Part 2

When:  Jun 27, 2023 from 13:00 to 17:00 (ET)
This program will be hosted virtually.


Pauline Funchain, MD - Cleveland Clinic Cancer Center
Krista M. Rubin, MS, FNP-BC - Massachusetts General Cancer Center
Yinghong Wang, MD, PhD, MSc - The University of Texas MD Anderson Cancer Center

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:

  • Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.
  • Outline best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.
  • Describe management approaches for difficult or refractory immune-related adverse events.
Attendees will also have an opportunity for connecting with experts in the immunotherapy field at the virtual event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

For more information on the program, click below.


View the SITC Meeting Code of Conduct.